Recent Work
-
A Strategy for Value-Based Drug Pricing Under the Inflation Reduction Act
To make sure that CMS is getting its money’s worth for today’s drugs, it must ensure that the maximum fair price is aligned to drug value.
Categorized in -
Comments to CMS on the Inflation Reduction Act’s Drug Price Negotiation Program
Over 20 researchers cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations for the Medicare Drug Price Negotiation Program
Categorized in -
Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
Developing a blueprint to overcome challenges in implementing new payment models will ensure better access.
Categorized in -
Improving Care of People with Serious Medical Illness: An Economic Research Agenda for Palliative Care
In 2020, Schaeffer Center established an Advisory Panel on Palliative Care. In this post, the panel outlines next steps to increase the quality of care of frail people with multiple chronic conditions.
Categorized in -
Create a U.S. Institute of Health Technology Assessment to Preserve Innovation and Control Costs
Americans need affordable, accessible and innovative health care. An important first step that can be taken without risking heavy-handed intervention is for Congress to establish an independent Institute of Health Technology Assessment.
Categorized in